Diabetes
-
Medtronic launches insulin delivery system with Abbott-made sensor
The partnership is the first time Medtronic has integrated its insulin pumps with a sensor developed outside of the company.
By Elise Reuter • Dec. 3, 2025 -
CMS finalizes competitive bidding changes to diabetes devices
AdvaMed supported adjustments made from a draft version but still has concerns about the impact on patient access.
By Elise Reuter • Dec. 1, 2025 -
Explore the Trendline➔
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
OIG report finds Medicare overpaying for CGMs and supplies
The CMS could use its competitive bidding program to address price concerns, after payments for the devices swelled over five years, the government watchdog said.
By Elise Reuter • Nov. 26, 2025 -
Abbott issues correction for millions of glucose sensors
The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.
By Elise Reuter • Nov. 24, 2025 -
Insulet unveils plans for new diabetes devices
The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.
By Elise Reuter • Nov. 24, 2025 -
Tidepool, Ōura partner on diabetes research
The collaboration will pair biometric data from the Oura ring with information from glucose sensors and insulin pumps.
By Elise Reuter • Nov. 6, 2025 -
Legislators object to proposed CMS payment changes for diabetes tech
In a letter to CMS Administrator Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce access to glucose monitors and insulin pumps.
By Elise Reuter • Nov. 4, 2025 -
Dexcom recalls G6 CGM app over software problem
A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download an update.
By Elise Reuter • Nov. 4, 2025 -
Q&A
Biolinq’s Jared Tangney on making CGMs unintimidating
The chief technology officer and co-founder explained the technology and design choices that went into Biolinq’s device, which he hopes will be easier to use than other glucose monitors.
By Elise Reuter • Oct. 20, 2025 -
Dexcom faces proposed class action suit over G7 CGM problems
The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.
By Elise Reuter • Oct. 20, 2025 -
Abbott CEO: ‘We’re right on time’ to the PFA party
As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.
By Elise Reuter • Oct. 15, 2025 -
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout
The Sanofi partnership will support clinical validation and regulatory submissions for Revvity’s new assay. Elsewhere, Kihealth raised $5 million in seed funding to launch its early detection test.
By Susan Kelly • Oct. 6, 2025 -
Biolinq gets FDA de novo nod for intradermal glucose sensor
The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin.
By Elise Reuter • Updated Sept. 29, 2025 -
Q&A
Que Dallara on Medtronic’s diabetes spinoff, pipeline and Abbott partnership
Dallara, president of Medtronic’s diabetes business, discussed the segment’s turnaround and why she sees a benefit in becoming a standalone firm.
By Elise Reuter • Sept. 25, 2025 -
Retrieved from Insulet on September 16, 2025
Insulet names new CFO; Dexcom CEO on leave
Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.
By Elise Reuter • Sept. 16, 2025 -
Senseonics inks deal to bring CGM commercialization back in-house
BTIG analysts said Senseonics is doubling down on its belief an inflection point in patient demand is imminent, but the company will need a large sales force to win market share.
By Nick Paul Taylor • Sept. 8, 2025 -
Dexcom to lay off about 350 people
The diabetes technology company said the cuts are part of broader changes to its structure, including eliminating operations roles in San Diego and shifting those positions to Arizona.
By Elise Reuter • Sept. 4, 2025 -
Medtronic advances Abbott partnership with FDA nod
The company received FDA authorization to pair its 780G insulin pump with a glucose sensor made by Abbott, and to use the device for Type 2 diabetes.
By Elise Reuter • Sept. 2, 2025 -
Insulet promotes Eric Benjamin to chief operating officer
As new CEO Ashley McEvoy works to build the brand globally, the diabetes tech company also hired Manoj Raghunandanan as chief growth officer.
By Elise Reuter • Aug. 26, 2025 -
Retrieved from Luna Health on August 20, 2025
Luna Health raises $23.6M for tiny insulin patch pump
The startup intends to make a small patch pump with a closed-loop algorithm for nighttime glucose control.
By Elise Reuter • Aug. 20, 2025 -
Tandem, Insulet monitoring CMS payment proposal for diabetes tech
The proposal would introduce competitive bidding for insulin pumps and change how Medicare pays for diabetes devices, if finalized.
By Elise Reuter • Aug. 8, 2025 -
Tandem insulin pump malfunction linked to 59 injuries
A problem with speakers in Tandem’s t:slim X2 insulin pumps can cause insulin delivery to stop, the company said.
By Elise Reuter • Aug. 7, 2025 -
Dexcom raises sales expectations, discusses G8 plans
Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and over-the-counter devices to drive future growth.
By Elise Reuter • July 31, 2025 -
Dexcom CEO Kevin Sayer to step down
Jake Leach will take over the role at the start of 2026, with Sayer remaining chairman of the board after the transition.
By Elise Reuter • Updated July 31, 2025 -
Medtronic receives Type 2 label expansion for MiniMed 780G in Europe
The CE mark also allows Medtronic’s automated insulin delivery system to be used during pregnancy and by children as young as 2.
By Elise Reuter • July 23, 2025